Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 36 studies | 35% ± 14% | |
endothelial cell | 32 studies | 34% ± 12% | |
memory B cell | 20 studies | 30% ± 6% | |
naive B cell | 19 studies | 29% ± 7% | |
plasma cell | 15 studies | 34% ± 19% | |
macrophage | 15 studies | 36% ± 19% | |
regulatory T cell | 14 studies | 22% ± 8% | |
microglial cell | 12 studies | 44% ± 16% | |
fibroblast | 11 studies | 28% ± 9% | |
non-classical monocyte | 10 studies | 24% ± 11% | |
plasmablast | 9 studies | 37% ± 19% | |
capillary endothelial cell | 9 studies | 28% ± 12% | |
myeloid cell | 9 studies | 38% ± 13% | |
ciliated cell | 9 studies | 24% ± 9% | |
pericyte | 9 studies | 27% ± 10% | |
GABAergic neuron | 8 studies | 38% ± 16% | |
plasmacytoid dendritic cell | 8 studies | 22% ± 8% | |
dendritic cell | 8 studies | 42% ± 15% | |
astrocyte | 8 studies | 29% ± 11% | |
monocyte | 8 studies | 32% ± 15% | |
classical monocyte | 7 studies | 23% ± 8% | |
endothelial cell of lymphatic vessel | 7 studies | 38% ± 13% | |
oligodendrocyte | 7 studies | 26% ± 9% | |
oligodendrocyte precursor cell | 7 studies | 26% ± 10% | |
CD4-positive, alpha-beta T cell | 6 studies | 23% ± 6% | |
glutamatergic neuron | 6 studies | 44% ± 21% | |
basal cell | 6 studies | 33% ± 22% | |
CD8-positive, alpha-beta T cell | 6 studies | 21% ± 6% | |
endothelial cell of artery | 6 studies | 24% ± 8% | |
smooth muscle cell | 6 studies | 26% ± 8% | |
epithelial cell | 5 studies | 43% ± 20% | |
club cell | 5 studies | 25% ± 7% | |
adipocyte | 5 studies | 22% ± 7% | |
cardiac muscle cell | 5 studies | 32% ± 9% | |
vein endothelial cell | 5 studies | 31% ± 15% | |
T cell | 5 studies | 30% ± 8% | |
type I pneumocyte | 5 studies | 25% ± 7% | |
type II pneumocyte | 5 studies | 29% ± 8% | |
interneuron | 5 studies | 38% ± 19% | |
precursor B cell | 4 studies | 29% ± 5% | |
immature B cell | 4 studies | 33% ± 9% | |
mast cell | 4 studies | 30% ± 15% | |
lymphocyte | 4 studies | 42% ± 13% | |
retinal rod cell | 4 studies | 19% ± 3% | |
respiratory goblet cell | 4 studies | 30% ± 12% | |
endothelial cell of vascular tree | 4 studies | 40% ± 14% | |
leukocyte | 4 studies | 41% ± 14% | |
natural killer cell | 4 studies | 26% ± 4% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 17% ± 2% | |
neuron | 4 studies | 42% ± 17% | |
abnormal cell | 4 studies | 43% ± 18% | |
IgA plasma cell | 4 studies | 30% ± 14% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 25% ± 7% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 25% ± 7% | |
glomerular endothelial cell | 3 studies | 33% ± 2% | |
GABAergic interneuron | 3 studies | 24% ± 9% | |
glial cell | 3 studies | 19% ± 1% | |
squamous epithelial cell | 3 studies | 38% ± 19% | |
mesothelial cell | 3 studies | 25% ± 7% | |
mononuclear phagocyte | 3 studies | 40% ± 9% | |
secretory cell | 3 studies | 25% ± 8% | |
germinal center B cell | 3 studies | 37% ± 6% | |
hepatocyte | 3 studies | 32% ± 14% | |
alveolar macrophage | 3 studies | 37% ± 11% | |
mural cell | 3 studies | 34% ± 13% | |
mucus secreting cell | 3 studies | 27% ± 4% | |
IgG plasma cell | 3 studies | 32% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4058.96 | 1445 / 1445 | 100% | 52.61 | 183 / 183 |
lung | 100% | 5826.56 | 578 / 578 | 100% | 35.03 | 1154 / 1155 |
bladder | 100% | 4041.14 | 21 / 21 | 100% | 30.65 | 503 / 504 |
breast | 100% | 4465.34 | 459 / 459 | 100% | 35.89 | 1113 / 1118 |
ovary | 100% | 3890.31 | 180 / 180 | 99% | 24.78 | 426 / 430 |
stomach | 100% | 2797.60 | 359 / 359 | 99% | 31.76 | 283 / 286 |
uterus | 100% | 4382.54 | 170 / 170 | 99% | 27.50 | 453 / 459 |
thymus | 100% | 4436.70 | 653 / 653 | 99% | 21.66 | 596 / 605 |
intestine | 100% | 3961.36 | 966 / 966 | 98% | 23.98 | 519 / 527 |
prostate | 100% | 3319.97 | 245 / 245 | 97% | 20.66 | 489 / 502 |
pancreas | 98% | 1805.22 | 322 / 328 | 98% | 24.97 | 175 / 178 |
skin | 100% | 5077.65 | 1809 / 1809 | 95% | 21.91 | 450 / 472 |
kidney | 100% | 2447.89 | 89 / 89 | 95% | 20.86 | 859 / 901 |
brain | 80% | 1110.91 | 2120 / 2642 | 99% | 17.28 | 696 / 705 |
adrenal gland | 100% | 2549.40 | 258 / 258 | 78% | 9.24 | 179 / 230 |
liver | 99% | 1480.43 | 223 / 226 | 78% | 10.83 | 316 / 406 |
adipose | 100% | 5210.36 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6099.23 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 61.41 | 29 / 29 |
muscle | 100% | 5540.66 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7932.38 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 28.12 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.68 | 1 / 1 |
heart | 100% | 2727.78 | 857 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 6571.07 | 900 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 76% | 8.33 | 61 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043697 | Biological process | cell dedifferentiation |
GO_0071392 | Biological process | cellular response to estradiol stimulus |
GO_0035624 | Biological process | receptor transactivation |
GO_0032870 | Biological process | cellular response to hormone stimulus |
GO_0006338 | Biological process | chromatin remodeling |
GO_1902459 | Biological process | positive regulation of stem cell population maintenance |
GO_2000035 | Biological process | regulation of stem cell division |
GO_0045618 | Biological process | positive regulation of keratinocyte differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0046966 | Molecular function | nuclear thyroid hormone receptor binding |
GO_0016922 | Molecular function | nuclear receptor binding |
GO_0000993 | Molecular function | RNA polymerase II complex binding |
GO_0004402 | Molecular function | histone acetyltransferase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0030374 | Molecular function | nuclear receptor coactivator activity |
GO_0005515 | Molecular function | protein binding |
GO_0097718 | Molecular function | disordered domain specific binding |
Gene name | NCOA3 |
Protein name | Nuclear receptor coactivator Nuclear receptor coactivator 3 (NCoA-3) (EC 2.3.1.48) (ACTR) (Amplified in breast cancer 1 protein) (AIB-1) (CBP-interacting protein) (pCIP) (Class E basic helix-loop-helix protein 42) (bHLHe42) (Receptor-associated coactivator 3) (RAC-3) (Steroid receptor coactivator protein 3) (SRC-3) (Thyroid hormone receptor activator molecule 1) (TRAM-1) |
Synonyms | AIB1 BHLHE42 TRAM1 RAC3 |
Description | FUNCTION: Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit. |
Accessions | Q569F6 Q9Y6Q9 ENST00000371998.8 [Q9Y6Q9-1] ENST00000372004.7 [Q9Y6Q9-5] Q0IIN7 ENST00000371997.3 [Q9Y6Q9-3] |